FDA Rejects Lilly’s Eczema Treatment Over Third-Party Manufacturing Issues

FDA Rejects Lilly’s Eczema Treatment Over Third-Party Manufacturing Issues

Submitted by admin on October 2, 2023 - 10:36am
Source: 
BioSpace
News Tags: 
Eli Lilly
lebrikizumab
atopic dermatitis
eczema
FDA
drug manufacturing
Headline: 
FDA Rejects Lilly’s Eczema Treatment Over Third-Party Manufacturing Issues
snippet: 

The FDA has rejected Eli Lilly’s investigational antibody lebrikizumab for the treatment of moderate-to-severe atopic dermatitis due to manufacturing problems, the company announced on Monday.

Do Not Allow Advertisers to Use My Personal information